Medical isotope developer IsoRay Medical said that it has shipped a set of cesium-131 brachytherapy seeds to a Canadian customer as part of a research initiative.
The seeds will be used for research and development of cesium-131 in Canada, according to the Richland, WA-based firm. Cesium-131 is currently approved by Health Canada only for the treatment of low-risk prostate cancers, and IsoRay aims to gather clinical evidence to support clearance for a wide variety of malignant disease locations.
Related Reading
IsoRay touts cesium-131 colorectal treatment, January 21, 2010
IsoRay inks distribution deal with Oncura, December 4, 2009
IsoRay adds Canadian distributor, November 18, 2009
IsoRay touts cesium-131 treatment, September 28, 2009
IsoRay's 2009 results dip, September 24, 2009
Copyright © 2010 AuntMinnie.com
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
